Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age

• Main Authors: Raul E. Isturiz (Author), Cassandra Hall-Murray (Author), John M. McLaughlin (Author), Vincenza Snow (Author), Beate Schmoele-Thoma (Author), Chris Webber (Author), Allison Thompson (Author), Daniel A Scott (Author)
• Format: Book
• Published: Taylor & Francis Group, 2018-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction; Adults, particularly those with underlying chronic conditions, eg, cardiovascular, liver, and pulmonary diseases and diabetes mellitus, have a persistent pneumococcal disease burden. Thirteen-valent pneumococcal conjugate vaccine (PCV13) is recommended in the United States for all adul...